5 results
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa
To evaluate the ongoing safety, tolerability, and efficacy parameters of pegunigalsidase alfa in adult Fabry patients who have successfully completed studies PB-102-F20 and PB-102-F30, or completed at least 48 months in study PB-102-F03.
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
To evaluate the effect of pneumodilatation (PD) on prolonged dysphagia after Toupet or Nissen fundoplication compared to sham dilatation.
The aim of the study is to investigate the effect of vibrotactile feedback on exoskeleton use in people with complete spinal cord injury.